• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Compass Therapeutics, Inc. - Common Stock (NQ:CMPX)

5.350 +0.180 (+3.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Compass Therapeutics, Inc. - Common Stock

News headline image
Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 07, 2022
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference
November 22, 2021
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 12, 2021
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market
November 01, 2021
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Therapeutics Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market
November 01, 2021
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Reports the Advancement of CTX-009, a Bispecific Antibody, to Phase 2a Development in Patients with Biliary Tract Cancers (BTC), and the Clearance of a Key Clinical Hurdle
November 01, 2021
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 08, 2021
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Therapeutics and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 01, 2021
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Therapeutics to Present at the Citi 16th Annual Biopharma Virtual Conference
August 13, 2021
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.
May 13, 2021
From Compass Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap